May 4, 2026 | Biosimilars, Cost Savings, Drug costs, MedBen Rx, Rebates, Rx Costs, Savings
Specialty drugs account for more than half of total drug spend and are often the largest cost driver for employer pharmacy plans. A recent BenefitPRO article points to biosimilars as a practical solution — and for MedBen Rx clients, the effect is already clear, with...
Feb 23, 2026 | Biosimilars, Cost Savings, Drug costs, MedBen Rx, Rx Costs, Specialty Drugs
Specialty medications continue to dominate pharmacy spend, now accounting for 52% of all U.S. pharmaceutical sales, according to a recent report from the Healthcare Distribution Alliance. With costs often reaching tens — or even hundreds — of thousands of dollars per...
Jan 12, 2026 | Acquisition Cost Index (ACI) pricing, Biosimilars, Brand Name Drugs, Drug costs, High-value formulary, MedBen Rx, News, Patient assistance, Pharmacogenomics, Pharmacy
Pharmaceutical manufacturers are planning to raise list prices on at least 350 brand-name medications in the United States beginning in 2026, up from 250 drugs last year, according to new data from health care research firm 3 Axis Advisors. These increases reflect...
Dec 30, 2025 | Benefits preservation, Biosimilars, Client Feedback, Client Surveys, Direct-to-Employer Contracting, Forensic claims review, Innovations, Kurt Harden, MedBen Employees, Self-funding, Spending, Third party administration
On behalf of the MedBen team, I wish you a happy and healthy new year, and thank you for your continued trust in MedBen. Our commitment remains to be the benefits partner that employers prefer, and we value the opportunity to serve you. In my 35 years with MedBen,...
Oct 21, 2025 | biologics, Biosimilars, Cost Savings, Humira, Rx Costs, Savings, Stelara
To help clients more efficiently access the cost savings of biosimilars, MedBen Rx is introducing an advance notice model. Rather than requiring approval each time a new biosimilar becomes available, this proactive approach automatically adds new biosimilars to your...
Jul 29, 2025 | biologics, Biosimilars, Cost Savings, MedBen Rx, Pharmacy, Pharmacy Benefits Manager (PBM), Prescription, Rx Costs, Savings
The advantages of biosimilars – clinically equivalent versions of high-price biologic drugs – have been known for years. But despite their growing availability, adoption remains slow… in no small part because major PBMs are stifling uptake....
